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The prognostic impact of p53 immunostaining in a large series of tumours from epithelial ovarian cancer patients in a two-centre
study was analysed. The study population (n¼476) comprised of a retrospective series of 188 patients (Dutch cohort) and a
prospective series of 288 patients (Scottish cohort) enrolled in clinical trials. P53 expression was determined by
immunohistochemistry on tissue microarrays. Association with progression-free survival (PFS) and overall survival (OS) was
analysed by univariate and multivariate Cox regression analysis. Aberrant p53 overexpression was significantly associated with PFS in
the Dutch and Scottish cohorts (P¼0.001 and 0.038, respectively), but not with OS in univariate analysis. In multivariate analysis,
when the two groups were combined and account taken of clinical factors and country of origin of the cohort, p53 expression was
not an independent prognostic predictor of PFS or OS. In this well-powered study with minimal methodological variability, p53
immunostaining is not an independent prognostic marker of clinical outcome in epithelial ovarian cancer. The data demonstrate the
importance of methodological standardisation, particularly defining patient characteristics and survival end-point data, if biomarker
data from multicentre studies are to be combined.
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Ovarian cancer is the leading cause of death from gynaecological
cancer in the Western world. Overall survival (OS) for patients
with advanced disease (stage III and IV according to the
International Federation of Gynaecology and Obstetrics (FIGO);
Cancer Committee of the International Federation of Gynaecology
and Obstetrics, 1986) is only 15–25% at 5 years (Kristensen and
Trope, 1997). Clinical decision-making is currently based on so-
called ‘classical’ clinicopathological prognostic factors such as
tumour stage, differentiation grade and histomorphologic tumour
type. However, these prognostic factors do not allow viable
prediction of the outcome for the individual patient. Biological
behaviour of the tumour, response to chemotherapy and overall
patient survival vary greatly between apparently similar cases
(Friedlander, 1998). Identification of new prognostic factors would
be of great importance in predicting disease outcome, and
therefore guiding therapeutic choices (Arts et al, 2000).
One of the most studied prognostic markers in ovarian cancer so
far is the tumour suppressor gene p53. The p53 protein plays a key
role in cell cycle regulation and suppression of tumour develop-
ment. DNA damage results in increased levels of p53, which lead to
cell cycle arrest in G1 phase, followed by DNA repair or apoptosis
(Levine, 1997; Vogelstein et al, 2000). Mutations of the p53 gene as
determined by mutation analysis and/or positive immunohisto-
chemical (IHC) staining for p53 are common in ovarian cancer and
have been associated with poor clinical outcome. However,
results of the many studies on the prognostic value of p53
expression in ovarian cancer are inconclusive (Marks et al, 1991;
Hartmann et al, 1994; Van Der Zee et al, 1995; Allan et al, 1996;
Anttila et al, 1999; Ferrandina et al, 1999; Reles et al, 2001;
Nakayama et al, 2003; Nielsen et al, 2004). One of the most
important reasons for these conflicting results is the considerable
methodological variability among the different studies (Hall et al,
2004). The type of study design, assays used to study p53
expression, determination of cutoff points for aberrant p53
expression and the definition of study end points vary greatly
among different studies. Furthermore, most studies have a small
sample size and include patients with different treatment regimens
(Hall et al, 2004).
The aim of the present study was to investigate the prognostic
and predictive value of p53 expression in tumour samples from a
large group of ovarian cancer patient with clinical data collected
through centres in the United Kingdom and the Netherlands, and
to test the hypothesis that p53 status could be a reproducible
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smarker for clinical outcome following therapy in ovarian cancer.
We aimed to minimise variability in the study by using well-
defined patient populations, and by performing tissue microarray
(TMA) construction, IHC staining and scoring at one location.
PATIENTS AND METHODS
Study design and inclusion criteria
Our study population comprised of retrospective (188 Dutch
patients) and prospective (288 Scottish patients) data. Figure 1
describes the flow of patients through the study. In both the Dutch
and Scottish cohorts, the principal eligibility criterion was primary
chemonaive epithelial ovarian cancer of any histological subtype
or stage. Patients were excluded if they had benign and borderline
tumours, if they did not receive chemotherapy or if no clinical and
follow-up information was available. Furthermore, all cases with
o2 evaluable cores on TMA were excluded from analysis.
Wherever possible, we aimed to comply with the recently
published REMARK criteria for the reporting of prognostic factor
studies (McShane et al, 2005).
Patients, treatment and follow-up for Dutch patients
Since 1985, clinicopathologic and follow-up data of all malignant
epithelial ovarian cancer patients treated at the Department of
Gynaecological Oncology at the University Medical Centre
Groningen have been prospectively stored in a computerised
database. We retrospectively analysed the data of all patients
treated from 1985 to 2002 for which paraffin-embedded tumour
tissue was available.
Primary treatment for all patients consisted of surgery. The
standard surgical procedure was total abdominal hysterectomy,
bilateral salpingo-oophorectomy, omentectomy, multiple perito-
neal biopsies and peritoneal washings with cytology. All patients
were staged according to the FIGO classification (Cancer
Committee of the International Federation of Gynaecology and
Obstetrics, 1986). Tumours were graded and classified by a
gynaecological pathologist according to WHO criteria (Scully,
1999). Adjuvant chemotherapy consisted of different platinum-
based treatment regimens. Response to chemotherapy was
assessed using WHO criteria (World Health Organization, 1979).
After chemotherapy, patients were followed up to 10 years with
gradually increasing intervals. Follow-up data were completed for
all patients until March 2005. Median follow-up of patients still
alive at the time of analysis was 51.6 months (range 2.8–136.5
months).
Patients, treatment and follow-up for Scottish patients
Data from eight previous multicentre, UK and international
clinical trials managed through the Beatson Oncology centre,
CRUK Trials office, Glasgow, since 1989–2003 were stored in a
computerised database. Thirty-seven (12.8%) patients from the
Scottish cohort were recruited from outside the UK. The median
follow-up of patients still alive at the time of analysis was 44.3
months (range 1.32–137.4 months). Patients underwent surgery,
followed by randomisation onto an arm of the trial. Patients were
staged according to the FIGO classification, graded by WHO
criteria and all patients received adjuvant chemotherapy consisting
of platinum-based regimes, single-agent taxanes and other
chemotherapy regimes including melphalan and etoposide.
Response to chemotherapy was determined by either modified
SWOG criteria or radiological findings (Vasey et al, 2004).
Institutional review board approval
For Dutch patients, clinicopathological and follow-up data were
obtained during standard treatment and follow-up. For the present
study, all relevant data were retrieved from our database into a
separate anonymous database. In this separate database, patient
identity was protected by a study-specific, unique patient code,
which was known to only two dedicated data managers, who also
have responsibility for the larger database. In case of uncertainties
with respect to clinicopathologic and follow-up data, the larger
database could only be checked through the data managers,
thereby ascertaining the protection of patients’ identity. Owing to
these precautions for this study, no further institutional review
board approval was needed, according to Dutch law. For the
Scottish data, ethical approval was obtained from the relevant
MREC and LREC committees.
Tissue microarray construction
Tissue microarrays were constructed as described in previous
studies (Kononen et al, 1998; Hoos and Cordon-Cardo, 2001). In
summary, paraffin-embedded tumour tissue blocks and matching
haematoxylin–eosin (H&E)-stained slides were retrieved from the
pathology archives and representative areas of tumour were
marked on each H&E-stained slide. Four cores of 0.6mm
2 were
taken from each donor block and arrayed on a recipient paraffin
block using a precision instrument (Tissue Arrayer, Beecher
Instruments, Silver Spring, MD, USA). Using a microtome, 5mm
sections were cut from each TMA block and applied to
aminopropyltriethoxysilane-treated slides. All sections were
stained within 2 weeks of sectioning. The presence of tumour
tissue on the arrayed samples was verified on an H&E-stained
section.
For the Scottish group, donor blocks were retrieved from
patients recruited into seven clinical trials and TMAs were
constructed separately for each trial. For the Dutch group, tumour
tissue was arranged in eight TMA blocks. Duplicate cores of five
tumour samples, an ovarian cystadenoma and normal tissue
(fallopian tube, endometrial, endocervical and cervical tissue) were
included on each TMA block to ensure similarity of staining
between the slides and to study p53 expression in normal tissues.
Immunohistochemical staining of TMAs
Tissue microarray sections were dewaxed in xylene and rehydrated
through graded concentrations of ethanol to distilled water. For
antigen retrieval, the sections were boiled with ethylenediamine-
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Figure 1 A diagram illustrating the flow of patients through the study.
p53 staining in ovarian cancer tissue samples was analysed by TMA and
IHC. Data sets (blue boxes) from the Netherlands and Scotland were
combined. Analyses (white hexagons) and reasons for patient drop out are
indicated.
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stetraaceticacid buffer (pH 8) in a microwaveable pressure cooker
for 5min at full power.
Staining was performed in a Dako Autostainer (Dako, Cam-
bridgeshire, UK). Endogenous peroxidase activity was blocked by
incubating the slides in Dako Peroxidase Block for 5min. The
sections were incubated with normal goat serum for 20min,
followed by incubation with the primary antibody for 30min at
room temperature. The monoclonal mouse anti-human antibody
DO-7 (dilution 1:2000; Dako), which detects both wild-type and
mutant p53 protein, was used as the primary antibody. Detection
was by a goat anti-mouse/rabbit secondary antibody conjugated
with a peroxidase-labelled polymer (Dako EnVisionþ system).
The antigen–antibody reaction was visualised with 3,30-diamino-
benzidine for 10min and was enhanced in copper sulphate (5min).
Sections were counterstained with haematoxylin. Separate full
slides containing breast cancer tissue of known p53 status were
used as external positive and negative controls for p53 staining.
Two observers (PG and KH) independently scored IHC staining
of all TMAs without prior knowledge of the clinicopathological
information. The cases with a discrepant score by the two
observers were re-examined with a gynaecological pathologist,
until consensus was reached. Immunoreactivity for the DO-7
antibody was scored according to the intensity of nuclear staining
and to the percentage of positively stained tumour cells. Tumours
showing 450% immunostaining with moderate or strong intensity
were considered as having aberrant p53 immunostaining. This cut
point was based on the observation of weakly positive immuno-
staining in normal control tissues.
Statistical design and study end points
Statistical analysis was performed using the SPSS 12.01 software
package (SPSS Inc., Chicago, IL, USA). The three end points
investigated were progression-free survival (PFS), OS and response
to chemotherapy. Progression-free survival was defined as date of
surgery (Dutch) or randomisation on the trial (Scottish: within 6
weeks of surgery) until progression or death. Overall survival was
defined as date of surgery or randomisation onto the trial until
death. Response to chemotherapy was assessed by CA125
measurement, modified SWOG or RECIST criteria (Scottish
cohort) and WHO criteria (Dutch).
As ‘classic’ clinically useful clinicopathological factors, such as
stage, distinguish risk groups with a hazard ratio (HR) of
approximately 2, we set this as the target size of effect for p53.
Standard calculations were used to assess the power of the analysis
(Schmoor et al, 2000). The Dutch (N¼188) and Scottish (N¼288)
studies individually had a power of 95.7 and 99.5% to detect a HR
of 2, assuming a frequency of p53 abnormalities at 50 and 40%
censoring. To detect the more subtle effect size of HR 1.5, the
power of the respective studies was 57.7 and 76.0% (or 92.6% for
combined data).
Differences between the two patient groups were analysed using
w
2 tests for clinicopathological characteristics, and Kaplan–Meier
estimates for PFS and OS. w
2 tests were used to assess associations
between p53 expression and clinicopathological characteristics or
response to chemotherapy. Survival analysis was performed using
Cox proportional hazards model. The cut point for aberrant p53
staining was decided a priori, as described above, and p53 was
entered as a categorical variable. Categorised variables used for
univariate analysis included age (o58 or X58 years), stage (stage
I/II or stage III/IV), grade (grade I or grade II/III), histology
(serous or non-serous), residual disease (o2o rX2cm) and type
of chemotherapy (platinum, platinum/taxane or other). Univariate
analysis was stratified for chemotherapy. All variables, including
country of origin, were subsequently included in multivariate
analysis. For multivariate analysis of response to chemotherapy,
logistic regression was used. For this analysis, response was
entered as a categorical variable (complete and partial response vs
stable and progressive disease). To investigate if the country of
origin of the data or the type of chemotherapy affected the
relationship of p53 with clinical outcome, interaction tests were
performed within a Cox regression model. The 5% confidence level
was used to test for significance of interactions. All P-values were
two sided.
RESULTS
Clinicopathologic characteristics
Clinicopathologic data from both patient populations, separately
and combined (N¼476), are summarised in Table 1. Adjuvant
chemotherapy consisted of a platinum-containing regimen in 195
Table 1 Clinicopathological characteristics and results of p53 immuno-
staining
UK patients
(n¼288)
Dutch patients
(n¼188)
All patients
(n¼476)
Age (years)
Median 58 59 59
Range 23–87 22–83 22–87
PFS (months)
Median 13 18 15
Range 0–135 0–158 0–158
OS (months)
Median 30 33 31
Range 0–136 37–186 0–186
FIGO stage
Stage I 21 (7.3%) 23 (12.1%) 44 (9.2%)
Stage II 39 (13.5%) 18 (9.6%) 57 (12.0%)
Stage III 181 (62.8%) 117 (62.2%) 298 (62.6%)
Stage IV 47 (16.3%) 29 (15.4%) 76 (16.0%)
Missing 0 1 (0.5%) 1 (0.2%)
Tumour type
Serous 154 (53.5%) 105 (55.9%) 259 (54.4%)
Mucinous 14 (4.9%) 15 (8.0%) 29 (6.1%)
Clear cell 15 (5.2%) 13 (6.9%) 28 (5.9%)
Endometrioid 36 (12.5%) 26 (13.8%) 62 (13.0%)
Adenocarcinoma 37 (12.8%) 20 (10.6%) 57 (12.0%)
Other 30 (10.4%) 9 (4.8%) 39 (8.2%)
Missing 2 (0.7%) 0 2 (0.4%)
Tumour grade
Grade I 19 (6.6%) 23 (12.2%) 47 (9.9%)
Grade II 73 (25.3%) 42 (22.3%) 120 (25.2%)
Grade III 158 (54.9%) 96 (51.1%) 256 (53.8%)
Missing 38 (13.2%) 27 (14.4%) 53 (11.1%)
Residual disease
o2cm 140 (48.6%) 65 (34.6%) 207 (43.5%)
X2cm 142 (49.3%) 110 (58.5%) 250 (52.5%)
Missing 6 (2.1%) 13 (6.9%) 19 (4.0%)
Type of chemotherapy
Platinum containing 98 (34.0%) 95 (50.5%) 195 (41.0%)
Platinum and taxane
containing
165 (57.3%) 72 (38.3%) 237 (49.8%)
Other regimen 25 (8.7%) 21 (11.2%) 44 (9.2%)
P53 expression
Normal 133 (46.2%) 99 (52.7%) 228 (47.9%)
Aberrant 155 (53.8%) 89 (47.3%) 248 (52.1%)
FIGO¼International Federation of Gynaecology and Obstetrics; OS¼overall
survival; PFS¼progression-free survival.
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s(41.0%) patients and a platinum- and taxane-containing regimen
in 237 (49.8%) patients. Fourty-four (9.2%) patients were treated
with other treatment regimens, including melphalan and etopo-
side. Median PFS for the whole cohort was 14.7 months (95%
confidence interval (CI): 12.8–16.5) and median OS was 30.6
months (95% CI: 25.6–35.7).
Analysis of differences between the two patient groups showed
that the Scottish cohort had a higher proportion of cases with
smaller residual disease (49.6 vs 38.3%; P¼0.020), higher grade
tumours (92.4 vs 83.8%; P¼0.006) and proportion of patients
receiving platinum/taxane combination therapy (57.3 vs 38.3%;
P¼0.0002). All other factors were not significantly different
between the two data sets (age, P¼0.99; stage, P¼0.82 and
histology, P¼0.71). The Scottish cohort had worse PFS than the
Dutch (P¼0.023). The same trend was observed for OS, but this
effect was not significant (P¼0.073).
Immunohistochemistry
Frequencies of p53 staining intensity and percentage of positively
stained cells were equally distributed across the Dutch and Scottish
group (Table 1). The intensity of p53 staining was normal in 228
(47.9%) samples, and elevated in 248 (52.1%) samples.
Prognostic and predictive value of aberrant p53 staining,
scored for the Dutch and Scottish group separately
Owing to differences in the clinical characteristics of the cohorts,
we firstly performed our analysis for the Dutch and Scottish group
separately. Table 2 shows the relationship between p53 staining
and clinicopathological characteristics for the two patient groups
separately. For UK patients, excessive p53 staining was associated
with a high differentiation grade (P¼0.003), but not with other
adverse prognostic factors, such as a higher age, late stage disease,
a serous tumour type and 42cm residual disease. In the Dutch
group, a correlation existed between excessive p53 staining and
late-stage disease (P¼0.006), a serous tumour type (P¼0.04), a
high differentiation grade (Po0.001) and 42cm residual disease
(P¼0.002). Again, there was a lack of association between
excessive p53 staining and higher age. Investigating the apparent
difference in the relationship between p53 and clinical factors in
the two cohorts, a multivariate logistic regression suggested that
only grade was a significant predictor of p53 status (P¼2.07e-5,
odds ratio (OR)¼8.45, CI: 3.16–22.6) whereas all other factors,
including patient cohort (P¼0.898), were not.
Univariate survival analysis of PFS suggested that aberrant p53
staining was associated with a shorter PFS (Dutch cohort:
P¼0.001, HR¼1.93, 95% CI: 1.32–2.82; Scottish cohort:
P¼0.038, HR¼1.32, 95% CI: 1.02–1.72). A similar trend of p53
on OS was observed (Dutch cohort: P¼0.084, HR¼1.41, 95% CI:
0.96–2.07; Scottish cohort: P¼0.036, HR¼1.35, 95% CI: 1.02–
1.80). p53 was not associated with response to chemotherapy in
either cohort (Dutch cohort: P¼0.974; Scottish cohort: P¼0.139).
As the two cohorts were not equally balanced in terms of their
clinical characteristics and these may influence the effect of p53,
multivariate analysis accounting for all potential confounding
factors was essential for further analysis.
The results of multivariate analysis are shown in Table 3. In
multivariate analysis for PFS, including country of origin, aberrant
p53 staining was not a significant prognostic factor for poor PFS.
Country of origin was an independent predictor of PFS; patients in
the Scottish cohort tended to have shorter PFS, suggesting that
factors other than those measured in this study can influence when
a patient progresses (Table 3). Larger residual disease, late stage,
higher grade and ‘other’ chemotherapy were also predictors of
poor PFS.
For OS, similarly, excessive p53 staining was not associated with
poor survival. Larger residual disease, later stage, higher grade and
‘other’ chemotherapy compared to platinum alone were indepen-
dent predictors of poor OS. This analysis also suggested that
patients receiving platinum/taxane combination therapy had better
survival rates than patients receiving platinum therapy alone.
No interaction between country of origin and p53 staining was
observed to affect outcome (PFS, P¼0.099; OS, P¼0.411),
Table 2 Relationship of p53 expression with clinicopathological characteristics
UK patients Dutch patients
Normal p53 Excessive p53 P-value
a Normal p53 Excessive p53 P-value
a
Age (years)
o58 71 (52.2%) 65 (47.8%) 0.709 50 (56.2%) 39 (43.8%) 0.383
X58 76 (50.0%) 76 (50.0%) 49 (49.5%) 50 (50.5%)
FIGO stage
Stage I/II 30 (50.0%) 30 (50.0%) 0.856 29 (70.7%) 12 (29.3%) 0.006
Stage III/IV 117 (51.3%) 111 (48.7%) 69 (47.3%) 77 (52.7%)
Tumour type
Serous 74 (48.1%) 80 (51.9%) 0.273 48 (45.7%) 57 (54.3%) 0.040
Non-serous 72 (54.5%) 68 (45.5%) 51 (61.4%) 32 (38.6%)
Differentiation grade
Grade I 16 (84.2%) 3 (15.8%) 0.003 26 (92.9%) 2 (7.1%) o0.001
Grade II/III 112 (48.5%) 119 (51.5%) 64 (44.1%) 81 (55.9%)
Residual disease
o2cm 74 (52.9%) 66 (47.1%) 0.404 44 (67.7%) 21 (32.3%) 0.002
X2cm 68 (47.9%) 74 (52.1%) 49 (44.5%) 61 (55.5%)
Response to chemotherapy
CR/PR 27 (41.5%) 58 (58.5%) 0.139 39 (70.9%) 42 (71.2%) 0.974
SD/PD 21 (56.8%) 16 (43.2%) 16 (29.1%) 17 (28.8%)
CR¼complete response; FIGO¼International Federation of Gynaecology and Obstetrics; PD¼progressive disease; PR¼partial response; SD¼stable disease.
aP-values were
calculated using w
2 or Fisher’s exact test, where appropriate. Bold signifies Po0.05.
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ssuggesting that there were no methodological inconsistencies in
the IHC between cohorts that were influencing the survival
analysis. Also, no interaction between p53 and chemotherapy
was observed to affect outcome (PFS, P¼0.477; OS, P¼0.932),
suggesting that p53 was not a strong predictive marker of response
to chemotherapy in patients in the presence of taxane vs non-
taxane regimens. Multivariate analysis for factors affecting
response to chemotherapy suggested that low-grade (P¼0.015,
OR¼0.152, CI: 0.034–0.689) tumours had better response to
chemotherapy.
Multivariate analysis for PFS and OS using the
classification proposed by Lassus et al
A second classification of p53 IHC staining that groups cases with
no p53 staining as aberrant as well as cases with over 50% of cells
with moderate or strong intensity staining has been suggested to
be prognostic in serous ovarian tumours (Lassus et al, 2003).
However, independently testing this classification in serous
tumours from the present study in the multivariate setting
revealed no strong association of p53 with clinical outcome, when
account is taken that two classifications of p53 were investigated in
the statistical analysis (PFS, P¼0.094; HR¼1.48; OS, P¼0.035;
HR¼1.70, N¼225), whereas residual disease, grade and chemo-
therapy remained strong (Po¼0.001) independent prognostic
factors in both analyses. Using the response end point, again, p53
had no independent prognostic ability (P¼0.186; OR¼2.98)
whereas low grade (P¼0.020) and the Dutch cohort (P¼0.037)
were significantly associated with better response.
DISCUSSION
In the past two decades, a wealth of studies has been performed on
the prognostic value of p53 expression in ovarian cancer. A recent
meta-analysis by Crijns et al (2003) on prognostic factors in
ovarian cancer demonstrated p53 protein overexpression in 14–
79% of ovarian carcinomas. In the same report, data from different
studies were pooled, which revealed that patients with aberrant
p53 expression had significantly poorer survival at 1 and 5 years.
However, owing to the considerable methodological variability
among prognostic factor studies, results could only be combined
by accepting rather flexible inclusion criteria (Crijns et al, 2003).
For the present study, we aimed to analyse the prognostic and
predictive impact of p53 expression in a large study population
with sufficient statistical power. Our study highlights the
importance of standardisation of the methods used for storage
and staining of tumour tissue as well as the patient population,
data collection and determination of clinical end points. The
apparent differing association of p53 staining with classical
clinicopathological prognostic factors in the two cohorts could
be attributed to differences in the proportions of high- and low-
grade patients in the two cohorts. This demonstrates that the
particular case mix in a cohort can influence the apparent effect of
p53 staining.
Although we minimised variability in the quality of the clinical
data by using well-defined patient populations, differences in the
clinical characteristics of the patient cohorts meant that multi-
variate analysis of the prognostic value of p53 was required to
account for potentially confounding factors. However, differences
in survival between the two cohorts may have also arisen by
inconsistent definitions of survival end points, the aggressiveness
of chemotherapy or surgery in the two counties, or could have
been acting as a surrogate for effects that were not quantified in the
analysis such as surgical approach, performance status or
deprivation. A recent study has investigated the effect of surgery
on clinical outcome of ovarian cancer patients within the context
of a clinical trial (Crawford et al, 2005). This study indicated that
surgical practise differed between the UK and other countries,
mainly that more extensive surgery was performed in non-UK
countries. This observation may in part explain the differences in
PFS between countries, but also suggests that information
regarding surgery should be collected and accounted for in future
prognostic factor studies.
Methodological variability between the two groups was mini-
mised by performing TMA construction and IHC staining in the
same laboratory and by evaluation of all stainings by the same
observers. Results of several studies indicate that depending on the
fixative used for processing paraffin-embedded tumour tissue, and
the storage time of tissue sections, results of IHC staining may vary
and these are not routinely mentioned in the literature on ovarian
cancer (Prioleau and Schnitt, 1995; Dressler et al, 1999; Atkins
et al, 2004). In breast cancer, standard guidelines for utilisation of
formalin-fixed, paraffin-embedded tissue sections have recently
been proposed (Dressler et al, 1999). Implementation of such
guidelines should aid in achieving comparable results among
prognostic factor studies. Definitive, reliable evidence for the
possible prognostic value of p53 expression should be obtained
from large clinical trials with a standardised laboratory protocol
and data collection.
Strongly positive p53 staining is mostly associated with missense
mutations of the p53 gene. However, the use of IHC staining for
determination of p53 status may yield false-positive as well as
false-negative results. Positive staining in the absence of p53
mutations may occur when wild-type p53 is activated in response
to oncogenic stresses or interaction with viral oncoproteins (Lu
et al, 1992; Demers et al, 1994). Furthermore, stabilisation and
accumulation of wild-type p53 may result from disruption of the
p53–Mdm2 interaction or the expression of p14ARF (Midgley and
Lane, 1997; Zhang et al, 1998; Bartel et al, 2002). Conversely, false-
Table 3 Multivariate analysis of p53 (50%) on PFS and OS in Dutch and Scottish patients (cohorts combined)
PFS OS
P-value HR 95% CI P-value HR 95% CI
Dutch cohort
a 0.036 0.76 0.59–0.98 0.101 0.80 0.61–1.05
Age458 years 0.31 1.13 0.89–1.44 0.072 1.27 0.98–1.63
Residual disease 42cm o0.001 1.97 1.52–2.57 o0.001 1.94 1.47–2.57
Non-serous tumour type 0.092 0.81 0.64–1.04 0.611 0.94 0.72–1.21
Stage III/IV o0.001 2.14 1.45–3.17 o0.001 2.12 1.38–3.25
Grade II/III 0.001 2.53 1.45–4.44 0.001 2.65 1.46–4.79
Chemotherapy o0.001 o0.001
Platinum vs taxane and platinum 0.237 0.86 0.67–1.10 0.004 0.67 0.51–0.88
Other vs platinum o0.001 2.86 1.88–4.37 o0.001 2.46 1.61–3.73
Aberrant p53 staining 0.228 1.16 0.91–1.47 0.362 1.13 0.87–1.45
CI¼confidence interval; HR¼hazard ratio; OS¼overall survival; PFS¼progression-free survival.
aCategories are given relative to the baseline comparator group.
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p53 gene or by null mutations. Shahin et al (2000) performed
immunohistochemistry and p53 sequencing on tumour samples of
171 ovarian cancer patients. Their results showed that 32.6% of
tumours with a p53 mutation were DO-7 negative, of which 75%
carried a null mutation. Patients with p53 null mutations in their
tumours had an even poorer survival than patients with missense
mutations (Shahin et al, 2000). Two recent studies in early and
advanced ovarian cancer confirmed that cases with non-missense
mutations of the p53 gene indeed show a low rate of p53 protein
accumulation, and that positive p53 immunostaining frequently
occurs in tumours with a wild-type p53 gene. As a result, the
concordance between p53 mutation and positive immunostaining
was only about 70% (Wang et al, 2004a,b).
To avoid false-positive and false-negative staining results,
several approaches have been suggested. One approach was
suggested by Lassus et al (2003), who evaluated the prognostic
significance of p53 immunostaining in 522 serous ovarian
carcinomas using the TMA technique. Patients were divided into
two distinct groups based on DO-7 immunostaining, one with
aberrant (negative or strongly positive) p53 expression and a poor
disease outcome, and one with normal p53 expression and
relatively good outcome. The association of aberrant p53 staining
with a poor prognosis was independent of other prognostic factors
(Lassus et al, 2003). In the present study, we used the same
antibody and attempted to independently validate their findings.
However, we were not able to confirm their findings in our
analysis.
Other approaches that have been used include determination of
p53 status by SSCP, direct sequencing or the use of yeast p53
functional assays (FASAY). These approaches, however, are
limited by complexity, cost, and collection and storage require-
ments. Furthermore, mutation does not necessarily correlate with
loss of transcriptional activity. Recently, Nenutil et al (2005)
suggested the combined staining of p53 and mdm2 as a simple and
cost-effective method to increase the sensitivity and specificity of
p53 determination by IHC staining. Results of their study showed
that the combined immunostaining of p53 and mdm2 correctly
identifies 86.6% of p53 genotypes, as judged by FASAY.
In order to efficiently study p53 expression in a large cohort and
save material from the pathology archives, we have used the TMA
technique. This technique was developed by Kononen et al (1998)
in response to the need for faster approaches to validation of
tumour markers. The TMA technique has been validated for
different tumour types (Camp et al, 2000; Gillett et al, 2000; Rosen
et al, 2004). Rosen et al (2004) validated p53 staining on ovarian
cancer TMAs and showed that p53 expression of tissue cores
correctly represents the expression in a whole slide. The chance of
correctly representing a whole section with one 0.6mm core was
91%. The concordance rate increased to 97% when two cores were
evaluable and to 98% when three cores could be evaluated (Rosen
et al, 2004). To ensure p53 staining in the TMA adequately
represented p53 staining in the whole tumour, only cases with two
or more assessable cores were included in the analysis for the
present study.
Several lines of experimental laboratory-based evidence support
the concept that p53 is involved in the cellular response to
cytotoxic agents and that loss of p53 is associated with resistance
to agents such as cisplatin (Righetti et al, 1996; Buttitta et al, 1997;
Reles et al, 2001; Siddik, 2003). In contrast, p53-deficient cell
cultures show increased sensitivity to paclitaxel treatment or no
difference. Paclitaxel does not directly interact with DNA, but
exerts its antitumour activity by stabilising microtubule formation,
resulting in cell cycle arrest in the G2–M phase transition. A
delayed G1 arrest after paclitaxel treatment could reduce the
number of cells with wild-type p53 reaching G2, where paclitaxel
exerts its effects (Vasey et al, 1996; Wahl et al, 1996). Lavarino et al
(2000), who determined the p53 status of 48 ovarian tumours using
SSCP and sequence analysis as well as immunohistochemistry,
reported that patients with p53 mutant tumours had an increased
sensitivity to paclitaxel in combination with platinum compounds.
In the present study, there was no relationship between p53
expression and response to chemotherapy. This is in contrast to
previous much smaller studies (Righetti et al, 1996; Buttitta et al,
1997; Lavarino et al, 2000; Reles et al, 2001). Furthermore, we have
performed logistic regression analysis for the platinum/taxane-
and the platinum-treated group separately. P53 was not an
independent prognostic factor in these analyses.
In summary, we demonstrated that even with minimal
methodological variability, it was inappropriate to combine results
from two large, well-defined study populations without appro-
priately accounting for potential confounding clinical factors.
Although strongly positive p53 immunostaining tends to be
associated with a poor prognosis in a univariate analysis, this
relationship did not hold when accounting for other potentially
confounding factors. Standardisation of methods used to store
paraffin-embedded tumour tissue and perform IHC analysis, the
use of tumour tissue obtained in clinical trials with clearly defined
end points and clearly defined, stringent, inclusion criteria, may
further elucidate the prognostic impact of p53 immunostaining in
the future.
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